Nature Communications (Jan 2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- Douglas B. Johnson,
- Monica V. Estrada,
- Roberto Salgado,
- Violeta Sanchez,
- Deon B. Doxie,
- Susan R. Opalenik,
- Anna E. Vilgelm,
- Emily Feld,
- Adam S. Johnson,
- Allison R. Greenplate,
- Melinda E. Sanders,
- Christine M. Lovly,
- Dennie T. Frederick,
- Mark C. Kelley,
- Ann Richmond,
- Jonathan M. Irish,
- Yu Shyr,
- Ryan J. Sullivan,
- Igor Puzanov,
- Jeffrey A. Sosman,
- Justin M. Balko
Affiliations
- Douglas B. Johnson
- Department of Medicine, Vanderbilt University
- Monica V. Estrada
- Department of Pathology, Microbiology and Immunology, Vanderbilt University
- Roberto Salgado
- Department of Pathology, Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Boulevard de Waterloo 121
- Violeta Sanchez
- Department of Pathology, Microbiology and Immunology, Vanderbilt University
- Deon B. Doxie
- Department of Cancer Biology, Vanderbilt University
- Susan R. Opalenik
- Department of Medicine, Vanderbilt University
- Anna E. Vilgelm
- Department of Cancer Biology, Vanderbilt University
- Emily Feld
- Department of Medicine, Vanderbilt University
- Adam S. Johnson
- Department of Pathology, Microbiology and Immunology, Vanderbilt University
- Allison R. Greenplate
- Department of Pathology, Microbiology and Immunology, Vanderbilt University
- Melinda E. Sanders
- Department of Pathology, Microbiology and Immunology, Vanderbilt University
- Christine M. Lovly
- Department of Medicine, Vanderbilt University
- Dennie T. Frederick
- Department of Medicine, Massachusetts General Hospital
- Mark C. Kelley
- Department of Surgical Oncology, Vanderbilt University
- Ann Richmond
- Department of Cancer Biology, Vanderbilt University
- Jonathan M. Irish
- Department of Pathology, Microbiology and Immunology, Vanderbilt University
- Yu Shyr
- Department of Biostatistics, Vanderbilt University
- Ryan J. Sullivan
- Department of Veterans Affairs, Tennessee Valley Healthcare System
- Igor Puzanov
- Department of Medicine, Vanderbilt University
- Jeffrey A. Sosman
- Department of Medicine, Vanderbilt University
- Justin M. Balko
- Department of Medicine, Vanderbilt University
- DOI
- https://doi.org/10.1038/ncomms10582
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 10
Abstract
Immunotherapy is used to treat melanoma, however patient responses vary widely highlighting the need for factors that can predict therapeutic success. Here, the authors show that MHC-II molecules expressed by tumour cells are positively correlated with a good response to therapy and overall patient survival.
